The NHS should be wary about handing the pharma industry its credit card
By 
Andi Orlowski2026-10-28T05:18:00
The US-UK medicines deal will raise NHS drug costs by billions, forcing difficult choices over which services lose funding without additional government investment
Register with hsj.co.uk to read the rest of this article
Critical stories remain free for registered users
Certain articles and Insight pieces remain paying-subscriber only content
As a registered user you will get access to:
- Daily News: an essential email round-up of all the latest news, comment and best practice
- Breaking news headlines delivered directly to your inbox
- Limited access to hsj.co.uk
Already registered to HSJ? Sign in now